Literature DB >> 27021603

Gene Therapy for Hemophilia.

Arthur W Nienhuis1, Amit C Nathwani2, Andrew M Davidoff3.   

Abstract

Adeno-associated viral vectors have been developed for the treatment of hemophilia A and B. Derivation of vector particles is achieved after multiplasmid transfection of cells that package the vector genome to yield vector particles. To date, three clinical trials have been performed for hemophilia B. The results of these trials are described. The trial that we conducted with our collaborators has yielded evidence of clinical efficacy for hemophilia B. A vector for treating hemophilia A has been developed and a clinical trial is planned.

Entities:  

Mesh:

Year:  2016        PMID: 27021603     DOI: 10.1089/hum.2016.018

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  8 in total

1.  Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion.

Authors:  Longping Victor Tse; Kelli A Klinc; Victoria J Madigan; Ruth M Castellanos Rivera; Lindsey F Wells; L Patrick Havlik; J Kennon Smith; Mavis Agbandje-McKenna; Aravind Asokan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

Review 2.  Gene Therapy for Hemophilia.

Authors:  Arthur W Nienhuis; Amit C Nathwani; Andrew M Davidoff
Journal:  Mol Ther       Date:  2017-04-11       Impact factor: 11.454

3.  Long-Term Sustained Effect of Liver-Targeted Adeno-Associated Virus Gene Therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy.

Authors:  Javier Torres-Torronteras; Raquel Cabrera-Pérez; Ferran Vila-Julià; Carlo Viscomi; Yolanda Cámara; Michio Hirano; Massimo Zeviani; Ramon Martí
Journal:  Hum Gene Ther       Date:  2018-02-26       Impact factor: 4.793

Review 4.  Adeno-Associated Virus Gene Therapy for Liver Disease.

Authors:  Lisa M Kattenhorn; Christopher H Tipper; Lorelei Stoica; Deborah S Geraghty; Teresa L Wright; K Reed Clark; Samuel C Wadsworth
Journal:  Hum Gene Ther       Date:  2016-12       Impact factor: 5.695

5.  Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.

Authors:  Dany P Perocheau; Sharon Cunningham; Juhee Lee; Juan Antinao Diaz; Simon N Waddington; Kimberly Gilmour; Simon Eaglestone; Leszek Lisowski; Adrian J Thrasher; Ian E Alexander; Paul Gissen; Julien Baruteau
Journal:  Hum Gene Ther       Date:  2018-10-19       Impact factor: 5.695

6.  AAV-mediated gene therapy for galactosialidosis: A long-term safety and efficacy study.

Authors:  Huimin Hu; Rosario Mosca; Elida Gomero; Diantha van de Vlekkert; Yvan Campos; Leigh E Fremuth; Scott A Brown; Jason A Weesner; Ida Annunziata; Alessandra d'Azzo
Journal:  Mol Ther Methods Clin Dev       Date:  2021-10-28       Impact factor: 6.698

Review 7.  Directing the Way-Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery.

Authors:  Ricarda Carolin Steffens; Ernst Wagner
Journal:  Pharm Res       Date:  2022-09-15       Impact factor: 4.580

Review 8.  Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.

Authors:  Julien Baruteau; Simon N Waddington; Ian E Alexander; Paul Gissen
Journal:  J Inherit Metab Dis       Date:  2017-05-31       Impact factor: 4.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.